On Thursday 07/11/2024 the closing price of the Eli Lilly and Co. share was $949.61 on BTT.
Compared to the opening price on Thursday 07/11/2024 on BTT of $937.85, this is a gain of 1.24%.
Eli Lilly and Co.'s market capitalization is $901.78 B by 950.40 M shares outstanding.
Is Eli Lilly and stock a Buy, Sell or Hold?
Eli Lilly and stock has received a consensus rating of buy. The average rating score is and is based on 92 buy ratings, 7 hold ratings, and 0 sell ratings.What was the 52-week low for Eli Lilly and stock?
The low in the last 52 weeks of Eli Lilly and stock was 434.34. According to the current price, Eli Lilly and is 218.58% away from the 52-week low.What was the 52-week high for Eli Lilly and stock?
The high in the last 52 weeks of Eli Lilly and stock was 950.60. According to the current price, Eli Lilly and is 99.87% away from the 52-week high.What are analysts forecasts for Eli Lilly and stock?
The 99 analysts offering price forecasts for Eli Lilly and have a median target of 656.97, with a high estimate of 1,025.00 and a low estimate of 290.00. The median estimate represents a 144.51 difference from the last price of 949.40.Eli Lilly and Stock Snapshot
947.00
Bid
1.00
Bid Size
950.86
Ask
100.00
Ask Size
7/12/2024
Date
7:49 PM
Time
132,840.00
Volume
949.61
Prev. Close
937.85
Open
950.40 M
Number of Shares
934.03
Day Low
950.60
Day High
949.40
434.34
52 Week Low
950.60
52 Week High
949.40
4.52
Dividend in USD
0.78
Dividend Yield
100.48
P/E Ratio
89.59
Free Float in %
5.82
EPS in USD
11.35
Book Value per Share in USD
4.69
Cash Flow per Share in USD
Eli Lilly and News More News
Historical Prices for Eli Lilly and
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Eli Lilly and Analyst Data
Total Analysts: 99
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 290.00
Median: 656.97
Highest: 1,025.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Eli Lilly and Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 07/11/24 | Berenberg | Maintained Buy | $1000 | |||
| 07/11/24 | J.P. Morgan | Maintained Buy | $1000 | |||
| 07/10/24 | Barclays Capital | Maintained Buy | $1025 | |||
| 07/05/24 | Morgan Stanley | Maintained Buy | $1023 | |||
| 07/03/24 | BMO Capital Markets | Maintained Buy | $1001 | |||
| 07/01/24 | Cantor Fitzgerald | Maintained Buy | $885 | |||
| 06/24/24 | Jefferies & Company Inc. | Maintained Buy | $1015 | |||
| 06/24/24 | Bank of America Merrill Lynch | Maintained Buy | $1000 | |||
| 06/24/24 | Cantor Fitzgerald | Maintained Buy | $885 | |||
| 06/20/24 | Cantor Fitzgerald | Maintained Buy | $885 | |||
| 06/17/24 | Cantor Fitzgerald | Maintained Buy | $885 | |||
| 06/11/24 | Cantor Fitzgerald | Maintained Buy | $885 | |||
| 06/07/24 | Jefferies & Company Inc. | Maintained Buy | $957 | |||
| 05/14/24 | Argus Research Company | Maintained Buy | $840 | |||
| 05/01/24 | BMO Capital Markets | Maintained Buy | $1001 | |||
| 05/01/24 | J.P. Morgan | Maintained Buy | $900 | |||
| 04/30/24 | Cantor Fitzgerald | Maintained Buy | $885 | |||
| 04/18/24 | Cantor Fitzgerald | Maintained Buy | $815 | |||
| 04/15/24 | Cantor Fitzgerald | Maintained Buy | $815 | |||
| 04/11/24 | Goldman Sachs | Maintained Hold | $723 | |||
| 04/05/24 | Cantor Fitzgerald | Maintained Buy | $815 | |||
| 04/02/24 | Citigroup Corp. | Maintained Buy | $895 | |||
| 04/01/24 | Cantor Fitzgerald | Maintained Buy | $815 | |||
| 03/15/24 | J.P. Morgan | Maintained Buy | $850 | |||
| 03/01/24 | Bank of America Merrill Lynch | Maintained Buy | $1000 | |||
| 02/21/24 | DZ BANK | Downgraded to Buy | $820 | |||
| 02/20/24 | Cantor Fitzgerald | Maintained Buy | $815 | |||
| 02/16/24 | Morgan Stanley | Maintained Buy | $950 | |||
| 02/14/24 | Cantor Fitzgerald | Maintained Buy | $815 | |||
| 02/07/24 | Morgan Stanley | Maintained Buy | $805 | |||
| 02/07/24 | Barclays Capital | Maintained Buy | $810 | |||
| 02/07/24 | BMO Capital Markets | Maintained Buy | $865 | |||
| 02/06/24 | Wells Fargo & Co | Maintained Buy | $825 | |||
| 02/05/24 | Cantor Fitzgerald | Maintained Buy | $630 | |||
| 02/01/24 | Cantor Fitzgerald | Maintained Buy | $630 | |||
| 01/24/24 | Wells Fargo & Co | Maintained Buy | $700 | |||
| 01/23/24 | Cantor Fitzgerald | Maintained Buy | $630 | |||
| 01/23/24 | Barclays Capital | Maintained Buy | $680 | |||
| 12/21/23 | Daiwa Securities | Downgraded to Buy | $610 | |||
| 11/20/23 | Cantor Fitzgerald | Maintained Buy | $630 | |||
| 11/15/23 | Cantor Fitzgerald | Maintained Buy | $630 | |||
| 11/09/23 | Deutsche Bank | Maintained Hold | $535 | |||
| 11/08/23 | J.P. Morgan | Maintained Buy | ||||
| 11/03/23 | Morgan Stanley | Maintained Buy | $722 | |||
| 10/23/23 | Citigroup Corp. | Maintained Buy | $675 | |||
| 10/23/23 | Cantor Fitzgerald | Maintained Buy | $630 | |||
| 10/20/23 | UBS | Maintained Buy | $710 | |||
| 10/11/23 | Morgan Stanley | Maintained Buy | $673 | |||
| 10/09/23 | Cantor Fitzgerald | Maintained Buy | $630 | |||
| 10/09/23 | Wells Fargo & Co | Maintained Buy | $650 |
Eli Lilly and Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 42,925 | 52,954 | 62,528 | 68,889 | 79,822 |
| Dividend | 5.31 | 6.43 | 7.60 | 7.86 | 8.80 |
| Dividend Yield (in %) | 0.56 % | 0.68 % | 0.80 % | 0.83 % | 0.93 % |
| EPS | 13.67 | 19.20 | 25.15 | 28.89 | 35.41 |
| P/E Ratio | 69.46 | 49.45 | 37.75 | 32.87 | 26.81 |
| EBIT | 14,646 | 20,387 | 26,158 | 30,018 | 36,464 |
| EBITDA | 16,219 | 22,625 | 28,580 | 33,505 | 38,332 |
| Net Profit | 12,300 | 17,327 | 22,397 | 25,910 | 31,712 |
| Net Profit Adjusted | 12,318 | 17,377 | 22,465 | 25,910 | 31,712 |
| Pre-Tax Profit | 14,237 | 19,986 | 25,758 | 31,239 | 36,811 |
| Net Profit (Adjusted) | 13,699 | 19,296 | 24,616 | 29,159 | 33,755 |
| EPS (Non-GAAP) ex. SOE | 13.67 | 19.20 | 25.15 | 28.89 | 35.41 |
| EPS (GAAP) | 13.40 | 18.68 | 23.98 | 28.41 | 33.59 |
| Gross Income | 34,585 | 42,543 | 50,231 | 56,040 | 62,482 |
| Cash Flow from Investing | -5,220 | -7,104 | -9,030 | -8,327 | -9,648 |
| Cash Flow from Operations | 12,718 | 16,165 | 21,180 | 22,735 | 28,082 |
| Cash Flow from Financing | -5,220 | -7,104 | -9,030 | -8,327 | -9,648 |
| Cash Flow per Share | 13.27 | 17.71 | 23.51 | 30.23 | 39.29 |
| Free Cash Flow | 8,152 | 11,645 | 16,680 | 16,673 | 19,848 |
| Free Cash Flow per Share | 6.50 | 9.42 | 15.40 | 18.63 | 22.19 |
| Book Value per Share | 19.36 | 30.78 | 46.29 | 68.63 | 88.47 |
| Net Debt | 17,982 | 11,393 | 525 | -22,435 | -45,213 |
| Research & Development Exp. | 11,395 | 12,800 | 13,974 | 14,208 | 15,775 |
| Capital Expenditure | 3,326 | 3,629 | 3,662 | 3,158 | 3,245 |
| Selling, General & Admin. Exp. | 8,626 | 9,736 | 10,701 | 11,350 | 12,421 |
| Shareholder’s Equity | 18,011 | 28,404 | 42,751 | 56,584 | 83,451 |
| Total Assets | 71,205 | 82,642 | 97,554 | 102,417 | 130,401 |
|
Previous Quarter ending 06/30/24 |
Current Quarter ending 09/30/24 |
Next Quarter ending 12/31/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 18 | 18 | 18 | 23 | 23 |
| Average Estimate | 2.800 USD | 3.767 USD | 4.509 USD | 13.668 USD | 19.200 USD |
| Year Ago | 1.960 USD | -0.064 USD | 2.306 USD | 5.822 USD | - |
| Publish Date | 8/8/2024 | 10/30/2024 | 1/30/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 16 | 16 | 16 | 23 | 23 |
| Average Estimate | 10,004 USD | 11,334 USD | 12,730 USD | 42,925 USD | 52,954 USD |
| Year Ago | 8,312 USD | 9,499 USD | 9,353 USD | 34,124 USD | - |
| Publish Date | 8/8/2024 | 10/30/2024 | 1/30/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 34,124.10 | 28,541.40 | 28,318.40 | 24,539.80 | 22,319.50 | 24,555.70 | 22,871.30 |
| Change of sales in % | 19.56 | 0.79 | 15.40 | 9.95 | -9.11 | 7.36 | 7.77 |
| Gross profit on sales | 27,041.90 | 21,911.60 | 21,005.60 | 19,056.50 | 17,598.30 | 18,125.70 | 16,801.10 |
| Gross profit on sales change in % | 23.41 | 4.31 | 10.23 | 8.29 | -2.91 | 7.88 | 7.93 |
| Operating income | 10,325.40 | 8,280.40 | 7,548.10 | 6,849.60 | 5,789.50 | 6,186.80 | 4,931.20 |
| Operating income change in % | 24.70 | 9.70 | 10.20 | 18.31 | -6.42 | 25.46 | 27.38 |
| Income before tax | 6,554.60 | 6,806.40 | 6,155.50 | 7,229.90 | 5,265.90 | 3,795.70 | 2,197.40 |
| Income before tax change in % | -3.70 | 10.57 | -14.86 | 37.30 | 38.73 | 72.74 | -34.87 |
| Income after tax | 5,240.40 | 6,244.80 | 5,581.70 | 6,193.70 | 4,637.90 | 3,232.00 | -204.10 |
| Income after tax change in % | -16.08 | 11.88 | -9.88 | 33.55 | 43.50 | - | - |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 53,142.60 | 38,714.40 | 39,651.20 | 40,807.90 | 36,587.00 | 32,999.30 | 33,313.10 |
| Long-term liabilities per share | 27.23 | 22.71 | 25.79 | 29.61 | 25.91 | 19.97 | 17.07 |
| Equity | 10,863.70 | 10,775.40 | 9,154.80 | 5,825.20 | 2,699.10 | 10,909.10 | 11,667.90 |
| Equity change in % | 1.15 | 18.61 | 59.16 | 116.41 | -73.48 | -15.21 | -17.24 |
| Balance sheet total | 64,006.30 | 49,489.80 | 48,806.00 | 46,633.10 | 39,286.10 | 43,908.40 | 44,981.00 |
| Balance sheet total change in % | 29.33 | 1.40 | 4.66 | 18.70 | -10.53 | -2.38 | 15.91 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 37.78 | 31.55 | 31.06 | 26.89 | 23.85 | 23.76 | 21.74 |
| P/E ratio (year end quote, basic EPS) | 100.48 | 53.00 | 45.12 | 24.87 | 26.52 | 36.97 | - |
| P/E ratio (year end quote, diluted EPS) | 100.48 | 53.00 | 45.12 | 24.87 | 26.52 | 36.97 | - |
| P/E ratio (year end quote) | 100.48 | 53.00 | 45.12 | 24.87 | 26.52 | 36.97 | - |
| Dividend yield in % | 0.78 | 1.07 | 1.23 | 1.75 | 1.96 | 1.94 | 2.46 |
| Equity ratio in % | 16.83 | 21.52 | 18.40 | 12.10 | 6.64 | 22.38 | 25.77 |
| Debt ratio in % | 83.03 | 78.23 | 81.24 | 87.51 | 93.13 | 75.15 | 74.06 |
Eli Lilly and Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | 07/09/2024 | 3,500.00 | 96,943,810.00 | 944.90 | Sell | No |
| LILLY ENDOWMENT INC | 07/09/2024 | 9,285.00 | 96,947,310.00 | 944.06 | Sell | No |
| LILLY ENDOWMENT INC | 07/09/2024 | 4,519.00 | 96,956,595.00 | 943.09 | Sell | No |
| LILLY ENDOWMENT INC | 07/09/2024 | 2,198.00 | 96,961,114.00 | 941.96 | Sell | No |
| LILLY ENDOWMENT INC | 07/09/2024 | 29,147.00 | 96,963,312.00 | 940.87 | Sell | No |
| LILLY ENDOWMENT INC | 07/09/2024 | 92,882.00 | 96,992,459.00 | 939.95 | Sell | No |
| LILLY ENDOWMENT INC | 07/09/2024 | 28,486.00 | 97,085,341.00 | 939.11 | Sell | No |
| LILLY ENDOWMENT INC | 07/09/2024 | 14,916.00 | 97,113,827.00 | 938.03 | Sell | No |
| LILLY ENDOWMENT INC | 07/09/2024 | 25,067.00 | 97,128,743.00 | 936.90 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 200.00 | 97,153,810.00 | 928.25 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 400.00 | 97,154,010.00 | 927.30 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 1,500.00 | 97,154,410.00 | 926.23 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 1,585.00 | 97,155,910.00 | 924.71 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 3,864.00 | 97,157,495.00 | 923.70 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 5,088.00 | 97,161,359.00 | 922.61 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 1,550.00 | 97,166,447.00 | 921.45 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 4,446.00 | 97,167,997.00 | 920.37 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 11,390.00 | 97,172,443.00 | 919.41 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 18,992.00 | 97,183,833.00 | 918.35 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 22,438.00 | 97,202,825.00 | 917.47 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 12,899.00 | 97,225,263.00 | 916.49 | Sell | No |
| LILLY ENDOWMENT INC | 07/07/2024 | 9,241.00 | 97,238,162.00 | 915.62 | Sell | No |
| LILLY ENDOWMENT INC | 07/04/2024 | 1,829.00 | 97,247,403.00 | 916.25 | Sell | No |
| LILLY ENDOWMENT INC | 07/04/2024 | 50,540.00 | 97,249,232.00 | 915.14 | Sell | No |
| LILLY ENDOWMENT INC | 06/27/2024 | 1,441.00 | 97,367,369.00 | 915.02 | Sell | No |
Eli Lilly and Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Eli Lilly and Co. | 4.52 | 0.78 | USD |
| 2022 | Eli Lilly and Co. | 3.92 | 1.07 | USD |
| 2021 | Eli Lilly and Co. | 3.40 | 1.23 | USD |
| 2020 | Eli Lilly and Co. | 2.96 | 1.75 | USD |
| 2019 | Eli Lilly and Co. | 2.58 | 1.96 | USD |
| 2018 | Eli Lilly and Co. | 2.25 | 1.94 | USD |
| 2017 | Eli Lilly and Co. | 2.08 | 2.46 | USD |
| 2016 | Eli Lilly and Co. | 2.04 | 2.77 | USD |
| 2015 | Eli Lilly and Co. | 2.00 | 2.37 | USD |
| 2014 | Eli Lilly and Co. | 1.96 | 2.84 | USD |
| 2013 | Eli Lilly and Co. | 1.96 | 3.84 | USD |
| 2012 | Eli Lilly and Co. | 1.96 | 3.97 | USD |
| 2011 | Eli Lilly and Co. | 1.96 | 4.72 | USD |
| 2010 | Eli Lilly and Co. | 1.96 | 5.59 | USD |
| 2009 | Eli Lilly and Co. | 1.96 | 5.49 | USD |
| 2008 | Eli Lilly and Co. | 1.88 | 4.67 | USD |
| 2007 | Eli Lilly and Co. | 1.75 | 3.28 | USD |
| 2006 | Eli Lilly and Co. | 1.63 | 3.13 | USD |
| 2005 | Eli Lilly and Co. | 1.54 | 2.72 | USD |
| 2004 | Eli Lilly and Co. | 1.45 | 2.56 | USD |
| 2003 | Eli Lilly and Co. | 1.36 | 1.93 | USD |
| 2002 | Eli Lilly and Co. | 1.27 | 2.00 | USD |
| 2001 | Eli Lilly and Co. | 1.15 | 1.46 | USD |
| 2000 | Eli Lilly and Co. | 1.06 | 1.14 | USD |
| 1999 | Eli Lilly and Co. | 0.95 | 1.43 | USD |
*Yield of the Respective Date
Eli Lilly and Co. Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 2.800 USD | Q2 2024 Earnings Release | 08/08/2024 |
| Earnings Report | 3.767 USD | Q3 2024 Earnings Release | 10/30/2024 |
| Earnings Report | 4.509 USD | Q4 2024 Earnings Release | 01/30/2025 |
| Earnings Report | 3.580 USD | Q1 2025 Earnings Release | 04/24/2025 |
| Earnings Report | 3.860 USD | Q2 2025 Earnings Release | 08/05/2025 |
| Earnings Report | 4.770 USD | Q3 2025 Earnings Release | 11/04/2025 |
Eli Lilly and Co. Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 05/06/2024 |
Eli Lilly and Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Moody’s Daily Credit Risk Score
Eli Lilly and Shareholder
| Owner | in % |
|---|---|
| Freefloat | 89.59 |
| Lilly Endowment, Inc. | 10.41 |
| The Vanguard Group, Inc. | 7.53 |
| Vanguard Group, Inc. (Subfiler) | 7.28 |
| PNC Financial Services Group, Inc. (13F Subfiler) | 5.41 |
| State Street Corp. | 3.60 |
| Vanguard Total Stock Market ETF | 2.84 |
| Fidelity Management & Research Co. LLC | 2.70 |
| Capital Research & Management Co. (World Investors) | 2.58 |
| BlackRock Fund Advisors | 2.43 |
| PRIMECAP Management Co. | 2.24 |
| Vanguard 500 Index Fund | 2.15 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 2.05 |
| BlackRock Institutional Trust Co. NA | 1.92 |
| Geode Capital Management LLC | 1.74 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Eli Lilly and Management
| Name | Job |
|---|---|
| David A. Ricks | Chairman, President & Chief Executive Officer |
| Donald A. Zakrowski | Chief Accounting Officer & Vice President-Finance |
| Anat Ashkenazi | Chief Financial Officer & Executive President |
| David Hyman | Chief Medical Officer |
| Daniel M. Skovronsky | Chief Scientific Officer & Executive VP |
| Robert Conley | Development Leader-Neuroscience |
| Patrik Jonsson | EVP, President-Lilly Diabetes & Obesity |
| Alonzo Weems | Executive VP, Chief Ethics & Compliance Officer |
| Diogo Rau | Executive VP, Chief Information & Digital Officer |
| Eric Dozier | Executive VP-Human Resources & Diversity |
| Jacob S. van Naarden | Executive Vice President |
| Johna L. Norton | Executive Vice President-Global Quality |
| Anne E. White | Executive Vice President-Lilly Neuroscience |
| Jennifer Oleksiw | Global Chief Customer Officer & Vice President |
| Kim Macko | Head-Global Brand Development |
| Kimberly H. Johnson | Independent Director |
| Gabrielle G. Greene-Sulzberger | Independent Director |
| Mary Lynne Hedley | Independent Director |
| Jon Erik Fyrwald | Independent Director |
| Karen Walker | Independent Director |
| William G. Kaelin | Independent Director |
| Katherine Baicker | Independent Director |
| Marschall S. Runge | Independent Director |
| Ralph Alvarez | Independent Director |
| Jamere Jackson | Independent Director |
| Joe Fletcher | Investor Relations Contact |
| Juan Ricardo Luciano | Lead Independent Director |
| Edgardo Hernandez | President-Manufacturing Operations & Senior VP |
| Anat Hakim | Secretary, Executive VP & General Counsel |
| Andy Vicari | Senior Director & US Brand Leader-Insulins |
| Ilya Yuffa | Senior VP & President-Lilly Bio Medicines |
| Mark Genovese | Senior Vice President-Immunology Development |
| Travis Coy | VP, Head-Transactions & Business Development |
| Christian Nguyen | VP-Global Patient Outcomes & Real World Evidence |
| Ruth Gimeno | Vice President |
| Laura A. Lane | Vice President |
| Robert J. Heine | Vice President-Medical Affairs |
| Nathaniel R. Miles | Vice President-Strategic Initiatives |
| Gordon Brooks | Vice President-Strategy & Controller |